Crinetics Q2 FY26 net loss widens to $120.86 million; revenue climbs to $25.12 million

• Crinetics posted revenue of $25.12 million, up from $1.03 million a year earlier, driven by $24.04 million in PALSONIFY net product revenue.
• Net loss widened to $120.86 million, versus $115.64 million a year earlier, as R&D spending climbed to $99.85 million.
• SG&A expenses increased to $57.57 million on commercial infrastructure investment, timing of commercial spend, transaction-related costs tied to Vertex.
• Cash, cash equivalents, and investment securities rose to $1.2 billion as of June 30 from $1.0 billion at year-end.
• Vertex agreed to acquire Crinetics for $85 per share in cash, valuing equity at about $10 billion; deal expected to close in Q3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608031605PRIMZONEFULLFEED9802296) on August 03, 2026, and is solely responsible for the information contained therein.